ES2114524T3 - Agentes con accion selectiva sobre receptores de adenosina. - Google Patents

Agentes con accion selectiva sobre receptores de adenosina.

Info

Publication number
ES2114524T3
ES2114524T3 ES90105920T ES90105920T ES2114524T3 ES 2114524 T3 ES2114524 T3 ES 2114524T3 ES 90105920 T ES90105920 T ES 90105920T ES 90105920 T ES90105920 T ES 90105920T ES 2114524 T3 ES2114524 T3 ES 2114524T3
Authority
ES
Spain
Prior art keywords
carbon atoms
adenosine
hydrogen
proviso
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90105920T
Other languages
English (en)
Inventor
Norton P Peet
Nelsen L Lentz
Shyam Sunder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2114524T3 publication Critical patent/ES2114524T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

SON DESCUBIERTAS ADENOSINAS QUE ACTUAN SELECTIVAMENTE EN RECEPTORES DE ADENOSINA Y QUE ACTUAN EN GENERAL COMO ANTAGONISTAS DE ADENOSINA. DE LOS ESTUDIOS IN VITRO ES CONOCIDO QUE LOS EFECTOS FISIOLOGICOS ESPECIFICOS PUEDEN SER DISTINGUIDOS COMO RESULTADO DE ESTA SELECTIVIDAD Y QUE LA ACTIVIDAD DEL RECEPTOR DE ADENOSINA IN VITRO SE CORRELACIONA CON LA ACTIVIDAD DEL RECEPTOR DE ADENOSINA IN VIVO. LAS PREPARACIONES FARMACEUTICAS DE LOS COMPONENTES SOMETIDOS PUEDEN SER PREPARADOS EN LAS BASES DE LA ACTIVIDAD ENLAZANTE SELECTIVA DE LOS COMPONENTES DESCUBIERTOS AQUI, QUE INCREMENTARAN CIERTOS EFECTOS FISIOLOGICOS MIENTRAS SE MINIMIZAN OTROS, TALES COMO DISMINUIR LA PRESION SANGUINEA SIN DISMINUIR EL RITMO DEL CORAZON.
ES90105920T 1989-03-29 1990-03-28 Agentes con accion selectiva sobre receptores de adenosina. Expired - Lifetime ES2114524T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32991989A 1989-03-29 1989-03-29

Publications (1)

Publication Number Publication Date
ES2114524T3 true ES2114524T3 (es) 1998-06-01

Family

ID=23287579

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90105920T Expired - Lifetime ES2114524T3 (es) 1989-03-29 1990-03-28 Agentes con accion selectiva sobre receptores de adenosina.

Country Status (18)

Country Link
EP (1) EP0390112B1 (es)
JP (1) JP2954971B2 (es)
KR (1) KR0168647B1 (es)
CN (1) CN1034575C (es)
AT (1) ATE162791T1 (es)
AU (1) AU630439B2 (es)
CA (1) CA2013380C (es)
DE (1) DE69031989T2 (es)
DK (1) DK0390112T3 (es)
ES (1) ES2114524T3 (es)
FI (1) FI95910C (es)
GR (1) GR3026173T3 (es)
HU (1) HU206354B (es)
IL (1) IL93892A (es)
NO (1) NO173996C (es)
NZ (1) NZ233078A (es)
PT (1) PT93588B (es)
ZA (1) ZA902280B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022644D0 (en) * 1990-10-18 1990-11-28 Ici Plc Heterocyclic compounds
IT1254915B (it) * 1992-04-24 1995-10-11 Gloria Cristalli Derivati di adenosina ad attivita' a2 agonista
WO1993025677A1 (en) * 1992-06-12 1993-12-23 Garvan Institute Of Medical Research DNA SEQUENCES ENCODING THE HUMAN A1, A2a and A2b ADENOSINE RECEPTORS
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB9613021D0 (en) * 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
DE602004018637D1 (de) 2003-04-09 2009-02-05 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
WO2004092170A2 (en) 2003-04-09 2004-10-28 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines useful as a2a adenosine receptor antagon ists
US7674791B2 (en) 2003-04-09 2010-03-09 Biogen Idec Ma Inc. Triazolopyrazines and methods of making and using the same
JP2015172077A (ja) * 2015-06-24 2015-10-01 中国医学科学院葯物研究所 Ｎ６−置換アデノシン誘導体とｎ６−置換アデニン誘導体の鎮静、催眠、抗うつ、抗痙攣、抗てんかん、抗パーキンソン病と認知証予防・治療の用途
SG11201909811XA (en) * 2017-04-27 2019-11-28 Takeda Pharmaceuticals Co Heterocyclic compound
US11806350B2 (en) * 2020-11-19 2023-11-07 Ildong Pharmaceutical Co., Ltd. Prevention and/or treatment of CNS disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL262940A (es) * 1960-03-31
NL283192A (es) * 1961-09-14
NL128629C (es) * 1966-05-07
DE1795828A1 (de) * 1966-12-21 1975-11-27 Boehringer Mannheim Gmbh Adenosinderivate
DE2139107A1 (de) * 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
US3862189A (en) * 1973-08-14 1975-01-21 Warner Lambert Co Aralkyl-substituted purines and pyrimidines as antianginal bronchodilator agents
AU527013B2 (en) * 1979-01-10 1983-02-10 Imperial Chemical Industries Ltd. Pure during derivatives and defoliation of cotton
US4388308A (en) * 1980-06-09 1983-06-14 G.D. Searle & Co. N6 -[(2-Hydroxypropyl)aryl]adenosines
US4514405A (en) * 1981-09-17 1985-04-30 Merck Patent Gesellschaft Mit Beschrankter Haftung Use of adenosine derivatives as anticonvulsants
DE3587717T2 (de) * 1984-04-18 1994-04-28 Whitby Research Inc N-6-thienyl-substituierte Adenosinderivate als herzgefässerweiternde Mittel.
AU575438B2 (en) * 1984-10-26 1988-07-28 Warner-Lambert Company N6 - substituted deoxyribose analogues of adenosines
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
DE3712735A1 (de) * 1987-04-15 1988-11-10 Boehringer Mannheim Gmbh Neue pyrazolo(3,4-d)pyrimidine, verfahren zu ihrer herstellung und verwendung als arzneimittel
KR910700253A (ko) * 1989-01-31 1991-03-14 로버트 제이, 바란 N_6-치환-9-메틸아데닌: 신규한 부류의 아데노신 수용체 길항질

Also Published As

Publication number Publication date
HUT53648A (en) 1990-11-28
CN1034575C (zh) 1997-04-16
FI95910B (fi) 1995-12-29
KR900014389A (ko) 1990-10-23
NO173996C (no) 1994-03-02
DE69031989D1 (de) 1998-03-05
CN1045973A (zh) 1990-10-10
JP2954971B2 (ja) 1999-09-27
FI95910C (fi) 1996-04-10
NO901423L (no) 1990-10-01
AU630439B2 (en) 1992-10-29
PT93588A (pt) 1990-11-20
DK0390112T3 (da) 1998-09-23
CA2013380A1 (en) 1990-09-29
EP0390112B1 (en) 1998-01-28
EP0390112A3 (en) 1992-02-12
ATE162791T1 (de) 1998-02-15
HU206354B (en) 1992-10-28
HU901856D0 (en) 1990-08-28
NZ233078A (en) 1993-11-25
AU5221590A (en) 1990-10-04
CA2013380C (en) 2001-05-22
IL93892A (en) 1994-11-28
GR3026173T3 (en) 1998-05-29
ZA902280B (en) 1990-12-28
NO173996B (no) 1993-11-22
JPH02289570A (ja) 1990-11-29
KR0168647B1 (ko) 1999-01-15
DE69031989T2 (de) 1998-09-03
NO901423D0 (no) 1990-03-28
PT93588B (pt) 1996-08-30
EP0390112A2 (en) 1990-10-03
FI901549A0 (fi) 1990-03-28

Similar Documents

Publication Publication Date Title
ES2114524T3 (es) Agentes con accion selectiva sobre receptores de adenosina.
ES2007411A6 (es) Procedimiento de preparar nuevos agentes psicoestimulantes.
DK535789D0 (da) Pyrimidindionderivater, fremgangsmaade til fremstilling heraf og antiarytmika omfattende samme
AU562260B2 (en) Benzoylurea compounds
KR880011155A (ko) 이미다조피리딘유도체, 그의 제법 및 치료에의 응용
CA2038747A1 (en) Selective adenosine receptor agents
MXPA04004826A (es) Antagonista del receptor de quimioquinas y metodos para su uso.
JPS6461461A (en) Benzohetero ring derivative
EP0390111A3 (en) Selective adenosine receptor compounds
ES2008067T3 (es) Analogos de prostaciclina (pgi2).
EP0882734A3 (en) 5'-Deoxy-cytidine derivatives
DE3886085D1 (de) Glucopyranose-Derivate.
ES2032386T3 (es) Un procedimiento para la preparacion de un derivado de glucopiranosa.
KR950703572A (ko) A-2 수용체 친화성을 갖는 2-치환된 아데노신[2-Substituted adenosines with A-2receptor affinity]
DK0423870T3 (da) Dibenzodioxazecin- dibenzodioxaazacycloundecinderivater

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 390112

Country of ref document: ES